3/13/2019 8:55:35 AM
Lilly Announces Final Results Of Elanco Exchange Offer
3/13/2019 6:43:43 AM
Elanco Appoints Four New Members To Board
3/12/2019 6:49:13 AM
Eli Lilly Says Phase 3 RELAY Study Of CYRAMZA Met Its Primary Endpoint Of Progression-free Survival
3/11/2019 6:51:44 AM
Elanco Animal Health Completes Separation From Lilly; Says It Is Now A Fully Independent Company
3/11/2019 6:49:28 AM
Eli Lilly Says Offer For Elanco Exchange Offer Was Oversubscribed
3/7/2019 6:49:54 AM
Lilly Announces Final Exchange Ratio Of 4.5121 For Elanco Exchange Offer; Exchange Offer Scheduled To Expire On March 8
3/5/2019 6:46:57 AM
Lilly Receives FDA Priority Review Designation For Emgality Injection For Episodic Cluster Headache In Adults
3/4/2019 6:32:42 AM
Lilly To Introduce Lower-Priced Insulin; List Price Of Single Vial Will Be $137.35
3/1/2019 6:50:16 AM
Lilly To Present Data For Taltz And Mirikizumab At AAD Annual Meeting
2/19/2019 6:47:34 AM
Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain
2/15/2019 9:32:42 AM
Lilly Closes Acquisition Of Loxo Oncology